[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schnitzler-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schnitzler-syndrome":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100637948","a-study-to-assess-the-effectiveness-and-safety-of-canakinumab-in-clinical-use-in-patients-with-schnitzlers-syndrome-100637948",false,"NCT07598422","A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome","Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)","Inclusion criteria\n\n1\\. Patients diagnosed with Schnitzler's syndrome using canakinumab for the first time for the indication of Schnitzler's syndrome as described in the package insert.\n\nPatients starting treatment with canakinumab before conclusion of the contract for this study will also be included in the study so that all patients diagnosed with Schnitzler's syndrome who received canakinumab will be registered in this study.\n\nExclusion criteria\n\n1. Patients previously treated with canakinumab in Study IACT21071.\n2. All patients treated with canakinumab for the following indications:\n\n   Indications: Cryopyrin-associated periodic syndromes (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease), hyper immunoglobulin D (IgD) syndrome (mevalonate kinase deficiency), tumor necrosis factor (TNF) receptor-associated periodic syndrome, familial mediterranean fever, systemic juvenile idiopathic arthritis, adult-onset Still's disease.\n3. Patients receiving canakinumab for off-label use under the Clinical Trials Act or GCP (e.g., patient-proposed healthcare services, investigator-initiated clinical trial).","ALL","0 Years",{"count":19,"type":20},10,"ESTIMATED","OBSERVATIONAL","The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.",[24],"Schnitzler Syndrome",[26,27,28,29,30],"Schnitzler's syndrome","Canakinumab","ILARIS","Post-marketing surveillance","All-case surveillance","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-05-13",{"date":39,"type":20},"2032-06-30",{"name":41,"class":42},"Novartis Pharmaceuticals","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":53,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":52,"type":20},3500,"10 Years","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[56,24,57,58,59,60,61,62,63,64,65],"Hereditary Autoinflammatory Diseases","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":68,"type":35},"2025-07-10",{"date":70,"type":35},"2020-08-06",{"date":72,"type":20},"2030-08-06",{"name":74,"class":75},"University of Siena","OTHER",112]